Isaac X Pei

Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.

M. Zelefsky, B. Mychalczak, L. Happersett, 2019, International journal of radiation oncology, biology, physics.

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

Y. Yamada, M. Zelefsky, D. Spratt, 2013, European urology.

Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

M. Zelefsky, J. Reis-Filho, B. Weigelt, 2020, Journal of the National Cancer Institute.

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination

J. Reis-Filho, K. Offit, B. Weigelt, 2021, npj Breast Cancer.

Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination

J. Reis-Filho, K. Offit, B. Weigelt, 2021, NPJ breast cancer.